Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2006

View Archived Issues

Intranasal insulin demonstrates therapeutic benefits in AD

Facial rejuvenation product ICX-RHY completes phase I

Novartis steps up activities for flu cell culture vaccines

UMMS signs license and research agreements with CytoDyn for flu vaccines

German approval for new phosphate binding agent OsvaRen

Orphan drug designations for YSPSL in U.S. and Europe

Wyeth and ArQule present new gamma secretase inhibitors with Notch-sparing selectivity

Ovation launches NeoProfen for premature infants with patent ductus arteriosus

Nanobodies targeting amyloid-beta peptide

Studies detail metabolic effects, efficacy of aripiprazole in schizophrenia

Japanese researchers present novel Abeta aggregation inhibitor

Pfizer begins Exubera introduction with education and training program

aP2 implicated in allergic airway inflammation: possible link between metabolic and immune disorders

Ostarine phase II proof-of-concept study completes enrollment

Aridol filed for approval in Switzerland

Phase III begins for Actos + TAK-536 combination product

Novel BiTE molecule presented

Lilly and Alcon sign marketing collaboration for Arxxant

NDA submission for SPD-465 for ADHD

Foamix's betamethasone foam shows efficacy and good usability in psoriasis

New compounds for respiratory disorders reported in recent patent literature

Patents claim agents with potential for treatment of inflammatory disorders

Radiotherapy using a peptidic vector shows promise in malignant glioma treatment

Sanvar filed for esophageal variceal bleeding in France

In vitro and in vivo pharmacology of novel GluK5 receptor antagonist

Opana and Opana ER now available

Elaprase approved for Hunter's syndrome

New approvable letter for Thelin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...